Numbers of nucleated cells and anti-SRBC PFCs of spleen cells of PBSC chimeras
| Group . | Mice . | No. . | Spleen cells, no. × 107 . | Anti-SRBC PFCs, /5 × 105spleen cells6-150 . |
|---|---|---|---|---|
| Control | BALB/c | 3 | 13.0 ± 1.7 | 253 ± 54.9 |
| BXSB | 3 | 80.0 ± 10.5 | 3 ± 2.8 | |
| BXSB→BXSB | 3 | 46.8 ± 19.0 | 18 ± 4.6 | |
| BALB/c→B6 | 3 | 8.5 ± 4.0 | 8 ± 2.1 | |
| Prevention | BALB/c→BXSB | 5 | 10.6 ± 0.6 | 27 ± 18.76-151 |
| BALB/c+BXSB→BXSB | 5 | 17.7 ± 2.1 | 90 ± 23.56-151 |
| Group . | Mice . | No. . | Spleen cells, no. × 107 . | Anti-SRBC PFCs, /5 × 105spleen cells6-150 . |
|---|---|---|---|---|
| Control | BALB/c | 3 | 13.0 ± 1.7 | 253 ± 54.9 |
| BXSB | 3 | 80.0 ± 10.5 | 3 ± 2.8 | |
| BXSB→BXSB | 3 | 46.8 ± 19.0 | 18 ± 4.6 | |
| BALB/c→B6 | 3 | 8.5 ± 4.0 | 8 ± 2.1 | |
| Prevention | BALB/c→BXSB | 5 | 10.6 ± 0.6 | 27 ± 18.76-151 |
| BALB/c+BXSB→BXSB | 5 | 17.7 ± 2.1 | 90 ± 23.56-151 |
Primary anti-SRBC antibody productions were tested when the recipients were 48 weeks old.
Each mouse was injected intraperitoneally with 0.5 mL 2% spleen blood cells (SRBCs). At 5 days later, primary PFC responses were assessed. The results are expressed as the mean ± SD.
P < .05 for BALB/c→BXSB versus BALB/c+BXSB→BXSB prevention mice.